Relmada Therapeutics, Inc. (NASDAQ:RLMD) Shares Bought by Tang Capital Management LLC

Tang Capital Management LLC grew its stake in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 295.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 200,825 shares of the company’s stock after purchasing an additional 150,000 shares during the quarter. Tang Capital Management LLC’s holdings in Relmada Therapeutics were worth $104,000 as of its most recent filing with the Securities and Exchange Commission.

Separately, Renaissance Technologies LLC raised its holdings in Relmada Therapeutics by 535.5% during the fourth quarter. Renaissance Technologies LLC now owns 164,513 shares of the company’s stock worth $86,000 after purchasing an additional 138,625 shares in the last quarter. 45.24% of the stock is owned by institutional investors and hedge funds.

Relmada Therapeutics Trading Up 11.5%

Shares of RLMD opened at $0.46 on Monday. The company’s 50 day simple moving average is $0.34 and its 200-day simple moving average is $0.79. The firm has a market cap of $15.30 million, a PE ratio of -0.16 and a beta of 0.18. Relmada Therapeutics, Inc. has a 12-month low of $0.24 and a 12-month high of $4.47.

Relmada Therapeutics (NASDAQ:RLMD) last announced its earnings results on Monday, May 12th. The company reported ($0.58) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.27). As a group, equities research analysts forecast that Relmada Therapeutics, Inc. will post -2.73 EPS for the current fiscal year.

Relmada Therapeutics Profile

Relmada Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder.